Theralase Successfully Destroys Lung Cancer

Theralase Technologies Inc. (TSXV:TLT) has announced a significant breakthrough in the preclinical treatment of Non-Small Cell Lung Cancer (NSCLC). The company's lead compound, Rutherrin®, has shown promising results in preclinical experiments using a Lewis Lung Cancer (LLC1) orthotopic model.

In the experiments, Rutherrin® exhibited a higher retention rate in lung tumors compared to normal lung tissues. This enhanced selectivity improved the compound's effectiveness in targeting lung cancer. All animals treated with x-ray activated Rutherrin® survived, in contrast to those that received only x-ray treatment.

Tumor progression was significantly slower in mice treated with Rutherrin®, with some cases showing tumor regression. Theralase plans to initiate a Phase Ia clinical study for patients with GBM and NSCLC in 4Q2024, potentially expanding to other cancers such as pancreatic, prostate, kidney, and colorectal cancer pending sufficient capital.